Pembrolizumab and chemotherapy in non‐small cell lung cancer with EGFR ex20ins mutation: A case report
Abstract The efficacy of immunotherapy in non‐small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations is not well clarified, even though immunotherapy has brought revolutionary improvements in EGFR wild‐type NSCLC. In addition, pseudoprogression has increased t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-10-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14101 |